Progyny Q2 2026: Net income +64% to $28.1M on margin gains, offset by 3% revenue growth

Filed August 7, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 8, 2025 · ~2 min read

Key Changes

• high

  Revenue growth decelerated to 5.3% YoY ($350.5M), down from 13% in the prior year, reflecting the impact of a large client non-renewal that extended through H1 2025, partially offset by new client additions.

  MD&A: Revenue Growth verify on EDGAR →
• high

  The company repurchased $148.6M of stock in H1 2026 (6.7M shares at $22.08 average), completing the November 2025 up to $200M program and leaving $168.5M available under the May 2026 up to $200M authorization.

  Notes: Share Repurchase Programs verify on EDGAR →
• high

  Consolidated Appropriations Act of 2026 (signed Feb 3, 2026) enacted PBM reforms requiring 100% rebate pass-through to consumers and new disclosure/audit requirements, creating compliance obligations for Progyny Rx.

  Risk Factors: PBM Reform verify on EDGAR →